Ingrandire l'immagine: Andrea Pasta, gastroenterologo Genova

Dott. Andrea Pasta

Gastroenterologo · Altro sulle specializzazioni

Genova 2 indirizzi

25 recensioni
Tempo medio di risposta:

Esperienze

Il Dottor Andrea Pasta si laurea con lode nel 2019 in Medicina e Chirurgia presso l’Università degli Studi di Genova e consegue nel 2025 la Specializzazione con lode in Malattie dell’Apparato Digerente sempre presso il medesimo Ateneo.

Dal 2023 è vincitore di una borsa di studio per il conseguimento del titolo di Dottore di Ricerca in Emato-Oncologia e Medicina Interna Clinico-Traslazionale, portando un curriculum sulle Malattie dell’apparato digerente e del fegato.

È socio della SIGE – Società Italiana di Gastroenterologia e Endoscopia Digestiva e della SINGEM – Società Italiana di Neuro-Gastro-Enterologia e Mobilità, oltre ad essere membro dell’IG-IBD – Gruppo Italiano per lo studio delle Malattie Infiammatorie Intestinali.

Il Dottor Pasta ha partecipato a numerosi convegni e seminari spesso in qualità di Docente e Relatore e ha frequentato molteplici corsi di formazione e aggiornamento, concentrando la sua attività principalmente nell’ambito delle Malattie Infiammatorie Croniche Intestinali, patologie gastro-esofagee, epatopatie croniche ed epatocarcinoma.

È autore di oltre un centinaio di pubblicazioni scientifiche su riviste nazionali e internazionali.
Altro Su di me

Su di me

Il Dottor Andrea Pasta si laurea con lode nel 2019 in Medicina e Chirurgia presso l’Università degli Studi di Genova e consegue nel 2025 la Specializzazione con lode in Malattie dell’Apparato Digerente sempre presso il medesimo Ateneo.

Dal 2023 è vincitore di una borsa di studio per il conseguimento del titolo di Dottore di Ricerca in Emato-Oncologia e Medicina Interna Clinico-Traslazionale, portando un curriculum sulle Malattie dell’apparato digerente e del fegato.

È socio della SIGE – Società Italiana di Gastroenterologia e Endoscopia Digestiva e della SINGEM – Società Italiana di Neuro-Gastro-Enterologia e Mobilità, oltre ad essere membro dell’IG-IBD – Gruppo Italiano per lo studio delle Malattie Infiammatorie Intestinali.

Il Dottor Pasta ha partecipato a numerosi convegni e seminari spesso in qualità di Docente e Relatore e ha frequentato molteplici corsi di formazione e aggiornamento, concentrando la sua attività principalmente nell’ambito delle Malattie Infiammatorie Croniche Intestinali, patologie gastro-esofagee, epatopatie croniche ed epatocarcinoma.

È autore di oltre un centinaio di pubblicazioni scientifiche su riviste nazionali e internazionali.

Aree di competenza principali:

  • Gastroenterologia endoscopica

Principali patologie trattate

  • Malattie gastrointestinali
  • Reflusso gastroesofageo (esofagite)
  • Esofagite da reflusso
  • Epatite
  • Epatocarcinoma
  • +20 a11y_sr_more_diseases

Presso questo indirizzo visito

Adulti (Solo in alcuni indirizzi)

Tipologia di visite

In studio Visualizza gli indirizzi (2)

Foto e video

  • Andrea Pasta-0
  • Andrea Pasta-1
  • Andrea Pasta-2
  • Andrea Pasta-3
  • Andrea Pasta-4
  • Andrea Pasta-5
  • Andrea Pasta-6
  • Andrea Pasta-7
  • Andrea Pasta-8
  • Andrea Pasta-9
  • Andrea Pasta-10

Esperienze

Doctor
Andrea Pasta

gastroenterologo

25 recensioni

Formazione

  • Università degli Studi di Genova, Laurea in Medicina e Chirurgia
  • Università degli Studi di Genova, Specializzazione in Malattie dell'Apparato Digerente
  • Università degli Studi di Genova, Dottorato di Ricerca in Malattie dell'Apparato Digerente e del Fegato (in corso)

Patologie trattate

Mostra dettagli

Video

Competenze linguistiche

  • Inglese
  • Italiano

Pubblicazioni

  • Pasta A, Formisano E, Calabrese F, Apollonio M, Demarzo MG, Marabotto E, Furnari M, Giannini EG, Pisciotta L, Bodini G. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial. Eur J Clin Invest. 2025 Jan 24:e14389.
  • Pasta A, Facciorusso A, Plaz Torres MC, Giannini EG, Sacco R. Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META-analysis. Eur J Clin Invest. 2025 Feb 12:e70000
  • Savarino, V., Visaggi, P., Marabotto, E., Bertin, L., Pasta, A., Calabrese, F., Zentilin, P., Ghisa, M., Ribolsi, M., Mari, A., Tolone, S., de Bortoli, N., & Savarino, E. V. (2025). Topical Protection of Esophageal Mucosa as a New Treatment of GERD. Journal of clinical gastroenterology, 10.1097/MCG.0000000000002128. Advance online publication.
  • Giannini EG, Pasta A, Plaz Torres MC, et al. Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma. Liver Int. 2025;45(2):e16185. doi:10.1111/liv.16185
  • Ferrari, D., Siboni, S., Sozzi, M., Visaggi, P., Kristo, I., Tolone, S., Marabotto, E., Bernardi, D., Schoppmann, S. F., Rogers, B. D., Hobson, A., Haworth, J., Lee, Y. Y., Louie, B. E., Masuda, T., Ivy, M. L., Milito, P., Centorrino, E., Theodorou, D., Triantafyllou, T., … De Bortoli, N. (2025). The Milan Score Predicts Objective Gastroesophageal Reflux Disease in Patients With Type 2 Esophagogastric Junction. Neurogastroenterology and motility, e14987. Advance online publication. https://doi.org/10.1111/nmo.14987
  • Giannini EG, Pasta A, Calabrese F, et al. Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis. Liver Int. 2025;45(1):e16222. doi:10.1111/liv.16222
  • Mocci, G., Tursi, A., Scaldaferri, F., Napolitano, D., Pugliese, D., Capobianco, I., Bartocci, B., Blasi, V., Savarino, E. V., Maniero, D., Redavid, C., Lorenzon, G., Cuomo, A., Donnarumma, L., Gravina, A. G., Pellegrino, R., Bodini, G., Pasta, A., Marzo, M., Serio, M., … Papa, A. (2024). Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study. Journal of clinical medicine, 13(23), 7192. https://doi.org/10.3390/jcm13237192
  • Pasta A, Calabrese F, Marabotto E, et al. Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn's Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies. Diseases. 2024;12(11):295. Published 2024 Nov 19. doi:10.3390/diseases12110295
  • Marabotto E, Calabrese F, Pasta A, et al. Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults. Expert Opin Pharmacother. 2024;25(17):2319-2325. doi:10.1080/14656566.2024.2427335
  • Pasta A, Calabrese F, Savarino EV, Giannini EG, Marabotto E. Role of prokinetics in ineffective esophageal motility: A call for broader consideration and future innovations. Neurogastroenterol Motil. 2025;37(2):e14961. doi:10.1111/nmo.14961
  • Calabrese F, Pasta A, Savarino EV, Savarino V, Giannini EG, Marabotto E. Expanding Insights on Ambulatory Reflux Monitoring: Future Directions and Clinical Integration. Am J Gastroenterol. Published online October 18, 2024. doi:10.14309/ajg.0000000000003080
  • Marabotto E, Pasta A, Calabrese F, et al. The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions. Visc Med. 2024;40(5):242-249. doi:10.1159/000536583
  • Visaggi P, Bertin L, Pasta A, et al. Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024. Expert Opin Pharmacother. 2024;25(15):2077-2088. doi:10.1080/14656566.2024.2416585
  • Kayali S, Calabrese F, Pasta A, et al. Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high-resolution manometry studies. Neurogastroenterol Motil. 2024;36(12):e14929. doi:10.1111/nmo.14929
  • Gravina, A. G., Pellegrino, R., Palladino, G., Imperio, G., Calabrese, F., Pasta, A., Giannini, E. G., Federico, A., & Bodini, G. (2024). Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand. Biomolecules, 14(9), 1164. https://doi.org/10.3390/biom14091164
  • Sorge, A., Aldinio, G., Marinoni, B., Visaggi, P., Penagini, R., Maniero, D., Ghisa, M., Marabotto, E., de Bortoli, N., Pasta, A., Dipace, V., Calabrese, F., Vecchi, M., Savarino, E. V., & Coletta, M. (2025). Distribution of esophageal inflammation in patients with eosinophilic esophagitis and its impact on diagnosis and outcome. Digestive and liver disease, 57(1), 260–265. https://doi.org/10.1016/j.dld.2024.08.049
  • Visaggi, P., Ghisa, M., Vespa, E., Barchi, A., Mari, A., Pasta, A., Marabotto, E., de Bortoli, N., & Savarino, E. V. (2024). Optimal Assessment, Treatment, and Monitoring of Adults with Eosinophilic Esophagitis: Strategies to Improve Outcomes. ImmunoTargets and therapy, 13, 367–383. https://doi.org/10.2147/ITT.S276869
  • Pasta A, Facchini C, Calabrese F, et al. Esophageal motor disorders across ages: A retrospective multicentric analysis. J Am Geriatr Soc. 2024;72(9):2782-2791. doi:10.1111/jgs.19068
  • Pasta A, Calabrese F, Bodini G. Response to Letter to Editor on "Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission". J Gastrointestin Liver Dis. 2024;33(2):281. Published 2024 Jun 29. doi:10.15403/jgld-5660
  • Pasta, A., Calabrese, F., Ghezzi, A., Savarino, E. V., Savarino, V., Zentilin, P., Furnari, M., Bodini, G., Giannini, E. G., & Marabotto, E. (2024). Diagnostic delay in achalasia. Digestive and liver disease, 56(11), 1839–1844. https://doi.org/10.1016/j.dld.2024.05.001
  • Pasta A, Calabrese F, Jaffe A, et al. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer. 2023;13(3):227-237. Published 2023 Oct 14. doi:10.1159/000533991
  • Calabrese F, Pasta A, Bodini G, et al. Editorial: Diagnosis of GERD in patients with extra-oesophageal symptoms-still a long way to go… Authors' reply'. Aliment Pharmacol Ther. 2024;59(9):1150-1151. doi:10.1111/apt.17960
  • Bertin, L., Barberio, B., Gubbiotti, A., Bertani, L., Costa, F., Ceccarelli, L., Visaggi, P., Bodini, G., Pasta, A., Sablich, R., Urbano, M. T., Ferronato, A., Buda, A., De Bona, M., Del Corso, G., Massano, A., Angriman, I., Scarpa, M., Zingone, F., & Savarino, E. V. (2024). Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease. Journal of clinical medicine, 13(6), 1539. https://doi.org/10.3390/jcm13061539
  • Pasta, A., Pieri, G., Plaz Torres, M. C., Trevisani, F., Giannini, E. G., & Italian Liver Cancer (ITA.LI.CA) Group (2024). Hepatocellular carcinoma in patients with autoimmune hepatitis. Journal of hepatology, 81(3), e131–e132. https://doi.org/10.1016/j.jhep.2024.03.025
  • Pasta, A., Pelizzaro, F., Marabotto, E., Calabrese, F., Formisano, E., Djahandideh Sheijani, S., Brandimarte, G., Manes, G., Gravina, A. G., & Savarino, E. V. (2024). Patient journey in gastroesophageal reflux disease: real-world perspectives from Italian gastroenterologists, primary care physicians, and ENT specialists. Therapeutic advances in gastroenterology, 17, 17562848241239590. https://doi.org/10.1177/17562848241239590
  • Calabrese, F., Pasta, A., Bodini, G., Furnari, M., Zentilin, P., Giannini, E. G., Maniero, D., Della Casa, D., Cataudella, G., Frazzoni, M., Penagini, R., Elena, A., de Bortoli, N., Visaggi, P., Savarino, V., Savarino, E., & Marabotto, E. (2024). Applying Lyon consensus criteria in the work-up of patients with extra-oesophageal symptoms - A multicentre retrospective study. Alimentary pharmacology & therapeutics, 59(9), 1134–1143. https://doi.org/10.1111/apt.17934
  • Giannini EG, Pasta A, Pieri G, et al. Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma. Liver Int. 2024;44(7):1588-1599. doi:10.1111/liv.15855
  • Pasta, A., Formisano, E., Calabrese, F., Plaz Torres, M. C., Bodini, G., Marabotto, E., Pisciotta, L., Giannini, E. G., & Furnari, M. (2024). Food Intolerances, Food Allergies and IBS: Lights and Shadows. Nutrients, 16(2), 265. https://doi.org/10.3390/nu16020265
  • Tursi, A., Mocci, G., Scaldaferri, F., Napolitano, D., Maresca, R., Pugliese, D., Semprucci, G., Savarino, E., Cuomo, A., Donnarumma, L., Bodini, G., Pasta, A., Maconi, G., Cataletti, G., Pranzo, G., Rodinò, S., Sebkova, L., Costa, F., Ferronato, A., Gaiani, F., … Papa, A. (2024). Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study. Expert opinion on biological therapy, 24(1-2), 101–109. https://doi.org/10.1080/14712598.2024.2309300
  • Pasta A, Calabrese F, Djahandideh Sheijani S, et al. Expression of epidermal growth factor receptor (EGFR) in systemic sclerosis patients (SSc) and gastro-oesophageal reflux disease (GORD). Immunol Lett. 2024;265:31-36. doi:10.1016/j.imlet.2023.106834
  • Bodini G, Ghezzi A, Pasta A, et al. Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission. J Gastrointestin Liver Dis. 2023;32(4):438-443. Published 2023 Dec 22. doi:10.15403/jgld-4932
  • Pasta, A., Calabrese, F., Plaz Torres, M. C., Bodini, G., Furnari, M., Savarino, E. V., Savarino, V., Giannini, E. G., & Marabotto, E. (2023). Albumin-bilirubin score in non-malignant liver diseases should be properly validated. World journal of gastroenterology, 29(46), 6089–6091. https://doi.org/10.3748/wjg.v29.i46.6089
  • Labanca S, Pasta A, Cariati S, et al. Letter to the Editor: Is CAD-LT score as a predictor of coronary artery disease following liver transplantation?. Liver Transpl. 2024;30(5):E28-E29. doi:10.1097/LVT.0000000000000315
  • Marabotto E, Pasta A, Calabrese F, et al. Is global score better than a single histological parameter for assessing microscopic esophagitis?. Neurogastroenterol Motil. 2024;36(1):e14685. doi:10.1111/nmo.14685
  • Pelizzaro F, Trevisani F, Simeon V, et al. Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection. Liver Int. 2023;43(12):2762-2775. doi:10.1111/liv.15719
  • Djahandideh Sheijani S, Calabrese F, Pasta A, et al. Clopidogrel-Induced Eosinophilic Colitis. ACG Case Rep J. 2023;10(8):e01118. Published 2023 Aug 3. doi:10.14309/crj.0000000000001118
  • Marten Canavesio Y, Pasta A, Calabrese F, et al. Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study. Rheumatol Int. 2024;44(12):2905-2910. doi:10.1007/s00296-023-05399-y
  • Pasta A, Calabrese F, Labanca S, et al. Safety and efficacy of venous thromboembolism prophylaxis in patients with cirrhosis: A systematic review and meta-analysis. Liver Int. 2023;43(7):1399-1406. doi:10.1111/liv.15609
  • Pasta A, Calabrese F, Giannini EG. Assessing the Short-Term Prognosis of Patients with Cirrhosis Using the DIC Scores. Thromb Haemost. 2023;123(7):744-746. doi:10.1055/a-2039-1575
  • Kayali S, Pasta A, Plaz Torres MC, et al. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver Int. 2023;43(1):8-17. doi:10.1111/liv.15419
  • Cremonini AL, Pasta A, Carbone F, et al. Lipoprotein(a) Modulates Carotid Atherosclerosis in Metabolic Syndrome. Front Mol Biosci. 2022;9:854624. Published 2022 Jun 8. doi:10.3389/fmolb.2022.854624
  • Kayali S, Pasta A, Pellicano R, et al. Effect of contrast-enhanced ultrasound (CEUS) on liver stiffness measurements obtained by transient and shear-wave elastography. Panminerva Med. 2022;64(4):479-484. doi:10.23736/S0031-0808.22.04719-X
  • Pasta A, Formisano E, Calabrese F, Marabotto E, Furnari M, Bodini G, Torres MCP, Pisciotta L, Giannini EG, Zentilin P. From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease. Microorganisms. 2025; 13(2):241
  • ARTICOLI 1. Formisano E*, Pasta A*, Cremonini AL, Favari E, Ronca A, Carbone F, Semino T, Di Pierro F, Sukkar SG, Pisciotta L. Efficacy of Nutraceutical Combination of Monacolin K, Berberine, and Silymarin on Lipid Profile and PCSK9 Plasma Level in a Cohort of Hypercholesterolemic Patients. J Med Food. 2020;23(6):658-666 (*co-first authorship) Journal Impact Factor: 2.0 2. Pasta A, Formisano E, Cremonini AL, Maganza E, Parodi E, Piras S, Pisciotta L. Diet and Nutraceutical Supplementation in Dyslipidemic Patients: First Results of an Italian Single Center Real-World Retrospective Analysis. Nutrients. 2020;12(7):2056. Published 2020 Jul 10. Journal Impact Factor: 5.0 3. Pasta A, Cremonini AL, Formisano E, Fresa R, Bertolini S, Pisciotta L. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies. Atherosclerosis. 2020 sep; 308:6-14 Journal Impact Factor: 5.7 4. Stefanutti C, Pisciotta L, Favari E, Di Giacomo S, Vacondio F, Zenti MG, Morozzi C, Berretti D, Mesce D, Vitale M, Pasta A, Ronca A, Garuti A, Manfredini M, Anglés-Cano E, Marcovina SM, Watts GF; Multidisciplinary International Group for Hemapheresis TherapY and MEtabolic DIsorders Control – ‘MIGHTY MEDIC.ORG’. Lipoprotein(a) concentration, genetic variants, apo(a) isoform size, and cellular cholesterol efflux in patients with elevated Lp(a) and coronary heart disease submitted or not to lipoprotein apheresis: An Italian case-control multicenter study on Lp(a). J Clin Lipidol. 2020;14(4):487-497.e1. Journal Impact Factor: 4.6 5. Arnaboldi L, Ossoli A, Giorgio E, Pisciotta L, Lucchi T, Grigore L, Pavanello C, Granata A, Pasta A, Arosio B, Azzolino D, Baragetti A, Castelnuovo S, Corsini A, Catapano AL, Calabresi L, Gomaraschi M. LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. Atherosclerosis. 2020;297:8-15. Journal Impact Factor: 5.7 6. Sukkar SG, Traverso N, Furfaro AL, Tasso B, Marengo B, Domenicotti C, Pisciotta L, Pasta A, Marinari UM, Pronzato MA, Cottalasso D. Whey proteins inhibit food intake and tend to improve oxidative balance in obese zucker rats. Eat Weight Disord. 2021;26(8):2453-2461. Journal Impact Factor: 2.8 7. Formisano E, Di Maio P, Ivaldi C, Sferrazzo E, Arieta L, Bongiovanni S, Panizzi L, Valentino E, Pasta A, Giudice M, Demontis S. Nutritional therapy for patients with coronavirus disease 2019 (COVID-19): Practical protocol from a single center highly affected by an outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nutrition. 2021;82:111048 Journal Impact Factor: 3.0 8. Sukkar SG, Cogorno L, Pisciotta L, Pasta A, Vena A, Gradaschi R, Dentone C, Guiddo E, Martino E, Beltramini S, Donini LM, Carmisciano L, Sormani MP, Bassetti M; GECOVID Study Group. Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission.Nutrition. 2021;89:111236. Journal Impact Factor: 3.0 9. Borro P, Ziola S, Pasta A, Trombini M, Labanca S, Marenco S, Solarna D, Pisciotta L, Baldissarro I, Picciotto A, Dellepiane S. Hepatic Elastometry and Glissonian Line in the Assessment of Liver Fibrosis. Ultrasound Med Biol. 2021;47(4):947-959. Journal Impact Factor: 2.6 10. Formisano E, Pasta A, Cremonini AL, Di Lorenzo I., Sukkar SG, Pisciotta L. Effects of a Mediterranean Diet, Dairy, and Meat Products on Different Phenotypes of Dyslipidemia: A Preliminary Retrospective Analysis. Nutrients. 2021 Apr 1;13(4):1161 Journal Impact Factor: 5.0 11. Cremonini AL, Formisano E, Pasta A, Borgarelli C, Fresa R, Pisciotta L. Evaluation of the efficacy of plant sterols supplement sterolip® ESI in patients with type IIA hypercholesterolemia in relation to Genetic variants modulating intestinal absorption of cholesterol. J Food Sci Nutr Res. 2021;04(03). Journal Impact Factor: not reported 12. Pasta A, Borro P, Cremonini AL, Formisano E, Tozzi G, Cecchi S, Fresa R, Labanca S, Djahandideh A, Sukkar SG, Picciotto A, Pisciotta L. Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: New perspectives from a single-center observational study.Pharmacol Res Perspect. 2021;9(5):e00820. Journal Impact Factor: 2.3 13. Kayali S, Pasta A, Pellicano R, Fagoonee S, Giuliana E, Facchini C, Pili S, Buccilli S, Labanca S, Borro P. Effect of contrast-enhanced ultrasound (CEUS) on liver stiffness measurements obtained by transient and shear-wave elastography. Panminerva Med. 2022;64(4):479-484. Journal Impact Factor: 4.3 14. Cremonini AL, Pasta A, Carbone F, Visconti L, Casula M, Elia E, Bonaventura A, Liberale L, Bertolotto M, Artom N, Minetti S, Contini P, Verzola D, Pontremoli R, Viazzi F, Viviani GL, Bertolini S, Pende A, Montecucco F, Pisciotta L. Lipoprotein(a) Modulates Carotid Atherosclerosis in Metabolic Syndrome. Front Mol Biosci. 2022;9:854624. Journal Impact Factor: 4.0 15. Marten Canavesio Y*, Pasta A*, Calabrese F et al. Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study. Rheumatol Int. 2024 Dec;44(12):2905-2910 (*co-first authorship) Journal Impact Factor: 2.9 16. Pasta A, Calabrese F, Djahandideh Sheijani S, Furnari M, Giannini EG, Grillo F, Marabotto E, Mastracci L, Murdaca G, Negrini S, Savarino EV, Savarino V, Zentilin P. Expression of epidermal growth factor receptor (EGFR) in systemic sclerosis patients (SSc) and gastro-oesophageal reflux disease (GORD). Immunol Lett. 2024 Feb;265:31-36. Journal Impact Factor: 2.8 17. Bodini G, Ghezzi A, Pasta A et al. Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission. JGLD, 32(4), 438–443. Journal Impact Factor: 2.0 18. Tursi A, Mocci G, Scaldaferri F, Napolitano D, Maresca R, Pugliese D, Semprucci G, Savarino E, Cuomo A, Donnarumma L, Bodini G, Pasta A, et al.. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study. Expert Opin Biol Ther. 2024 Jan-Feb;24(1-2):101-109 Journal Impact Factor: 4.0 19. Giannini EG, Pasta A, Pieri G, Plaz Torres MC, Marseglia M, Pelizzaro F, Sangiovanni A, Cabibbo G, Ghittoni G, Di Marco M, Foschi FG, Guarino M, Biasini E, Saitta C, Campani C, Svegliati-Baroni G, Gasbarrini A, Brunetto MR, Magalotti D, Azzaroli F, Mega A, Sacco R, Nardone G, Sacerdoti D, Masotto A, Vidili G, Bucci L, Vitale A, Trevisani F; Italian Liver Cancer (ITA.LI.CA) group. Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma. Liver Int. 2024 Jul;44(7):1588-1599. Journal Impact Factor: 5.2 20. Pasta A, Pelizzaro F, Marabotto E, Calabrese F, Formisano E, Djahandideh Sheijani S, Brandimarte G, Manes G, Gravina AG, Savarino EV. Patient journey in gastroesophageal reflux disease: real-world perspectives from Italian gastroenterologists, primary care physicians, and ENT specialists. Ther Adv Gastroenterol. 2024 Mar 22;17:17562848241239590. Journal Impact Factor: 3.4 21. Bertin L, Barberio B, Gubbiotti A, Bertani L, Costa F, Ceccarelli L, Visaggi P, Bodini G, Pasta A, Sablich R, et al. Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn’s Disease. Journal of Clinical Medicine. 2024; 13(6):1539. Journal Impact Factor: 2.9 22. Calabrese F, Pasta A, Bodini G, Furnari M, Zentilin P, Giannini EG, Maniero D, Della Casa D, Cataudella G, Frazzoni M, Penagini R, Elena A, de Bortoli N, Visaggi P, Savarino V, Savarino E, Marabotto E. Applying Lyon consensus criteria in the work-up of patients with extra-oesophageal symptoms - A multicentre retrospective study. Aliment Pharmacol Ther. 2024 May;59(9):1134-1143 Journal Impact Factor: 6.7 23. Agha A, Pasta A, Calabrese F, Anwar E, Taha M, Pedo VG, Al-Bluwi GSM, Giannini EG. Exploring new noninvasive parameters to predict oesophageal varices in patients with NAFLD-associated compensated liver cirrhosis. Prz Gastroenterol. 2025;20(1):48-54. Journal Impact Factor: 2.5 24. Pasta A, Calabrese F, Ghezzi A, Savarino EV, Savarino V, Zentilin P, Furnari M, Bodini G, Giannini EG, Marabotto E. Diagnostic delay in achalasia. Dig Liver Dis. 2024 Nov;56(11):1839-1844. Journal Impact Factor: 3.8 25. Pasta A, Facchini C, Calabrese F, Bodini G, De Bortoli N, Furnari M, Mari A, Savarino EV, Savarino V, Visaggi P, Zentilin P, Giannini EG, Marabotto E. Esophageal motor disorders across ages: A retrospective multicentric analysis. J Am Geriatr Soc. 2024 Sep;72(9):2782-2791. Journal Impact Factor: 4.5 26. Sorge A, Aldinio G, Marinoni B, Visaggi P, Penagini R, Maniero D, Ghisa M, Marabotto E, de Bortoli N, Pasta A, et al. Distribution of esophageal inflammation in patients with eosinophilic esophagitis and its impact on diagnosis and outcome. Dig Liver Dis. 2025 Jan;57(1):260-265. Journal Impact Factor: 3.8 27. Kayali S, Calabrese F, Pasta A, Marabotto E, Bodini G, Furnari M, Savarino EV, Savarino V, Giannini EG, Zentilin P. Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high-resolution manometry studies. Neurogastroenterol Motil. 2024 Dec;36(12):e14929. Journal Impact Factor: 3.3 28. Mocci G, Tursi A, Scaldaferri F, Napolitano D, Pugliese D, Capobianco I, Bartocci B, Blasi V, Savarino EV, Maniero D, Redavid C, Lorenzon G, Cuomo A, Donnarumma L, Gravina AG, Pellegrino R, Bodini G, Pasta A, Marzo M, ... Papa A. Long-Term Effectiveness and Safety of Ustekinumab in Crohn’s Disease: Results from a Large Real-Life Cohort Study. J Clin Med. 2024, 13, 7192 Journal Impact Factor: 2.9 29. Giannini EG, Pasta A, Plaz Torres MC, et al. Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma. Liver Int. 2025 Feb;45(2):e16185. Journal Impact Factor: 5.2 30. Pasta A, Formisano E, Calabrese F, et al. The use of the Crohn's disease exclusion diet (CDED) in adults with Crohn's disease: A randomized controlled trial. Eur J Clin Invest. 2025;55(6):e14389. Journal Impact Factor: 3.6 31. Visaggi P, Cohen DL, Marabotto E, Pasta A, Calabrese F, de Bortoli N, Farah A, Gargani A, Hindy J, Hijazi B, Abboud W, Ribolsi M, Bertin L, Savarino EV, Mari A. Esophageal motility disorders among elderly patients: An international multicenter study. Dig Liver Dis. 2025 Aug;57(8):1615-1621. Journal Impact Factor: 3.8 32. Pasta A, Pieri G, Plaz Torres MC, et al. Characteristics and Outcomes of Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. Dig Dis Sci. 2025 Aug;70(8):2865-2872. Journal Impact Factor: 2.5 33. Lahner E, Annibale B, Dilaghi E, Luciano Millado C, Lenti MV, Di Sabatino A, Miceli E, Massironi S, Zucchini N, Cannizzaro R, Realdon S, Losurdo G, Borraccino AV, Marabotto E, Giannini EG, Pasta A, et al. Clinical and Endoscopic-Histological Features of Multifocal and Corpus-Restricted Atrophic Gastritis Patients With Non-Cardia Gastric Cancer or Dysplasia: A Multicenter, Cross-Sectional Study. Clin Transl Gastroenterol. 2025 May 23;16(8):e00862. Journal Impact Factor: 3.0 34. Siboni S, De Maron R, Pasta A, Sozzi M, Calabrese F, Visaggi P, De Bortoli N, Hobson A, Haworth J, Bernardi D, Masuda T, Aldinio G, Coletta M, Penagini R, Savarino E, Asti E, Gyawali CP, Marabotto E. Assessment of Esophagogastric Junction Barrier Function With the Supine-Upright Transition of the Chicago Classification Protocol. Neurogastroenterol Motil. 2025 Dec;37(12):e70088. Journal Impact Factor: 3.3 35. Sacco R, Giannini EG, Tortora R, Di Costanzo GG, Mega A, Marzi L, Pieri G, Pasta A, et al. Lenvatinib Is Highly Effective in Patients with Hepatocellular Carcinoma Related to Both Metabolic Dysfunction-Associated Steatohepatitis and Alcoholic Etiology: A Propensity Score Analysis. Cancers (Basel). 2025 May 28;17(11):1808 Journal Impact Factor: 4.4 36. Giannini EG, Pasta A, Bucci L, et al. Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world study. Dig Liver Dis. 2025 Aug;57(8):1673-1682. Journal Impact Factor: 3.8 37. Formisano E, Vignati A, Bertolini A, Barreto Spandonari VM, Tafuro M, Pasta A, Sukkar SG, Pisciotta L. Decline in LDL-C control in patients with dyslipidemia treated with PCSK9-inhibitors: The role of obesity in LDL-C target achievement. J Clin Lipidol. 2025 Sep-Oct;19(5):1374-1384. Journal Impact Factor: 4.6 38. Calabrese F, Pasta A, Bodini G, Furnari M, Grillo F, Mastracci L, Savarino EV, Savarino V, Zentilin P, Giannini EG, Marabotto E. Autoimmune chronic atrophic gastritis: association between chronic proton pump inhibitors use and more severe atrophy and gastric intestinal metaplasia. Eur J Gastroenterol Hepatol. 2025 Aug 1;37(8):905-910. Journal Impact Factor: 1.8 39. Siboni S, Sozzi M, Visaggi P, Boveri S, Rogers BD, De Bortoli N, Hobson A, Louie BE, Lee YY, Tolone S, Marabotto E, Haworth J, Ivy ML, Cusmai L, Campioli E, Theodorou D, Triantafyllou T, Pasta A, et al. Combined Lyon and Milan Scores Predict Gerd Management Outcome Better Than Either Score Alone or Their Individual Components. Aliment Pharmacol Ther. 2025 Oct;62(7):710-721. Journal Impact Factor: 6.7 40. Furnari M, Calabrese F, Pasta A, Marabotto E, Barbera L, Bodini G, Savarino EV, Savarino V, Zentilin P, Giannini EG. Eosinophilic esophagitis is the leading cause of dysphagia in an outpatient setting. Eur J Gastroenterol Hepatol. 2026 Feb 1;38(2):148-153. Journal Impact Factor: 1.8 41. Vitale A, Kim JS, Cabibbo G, Casadei-Gardini A, Iavarone M, Rimassa L, Ponziani FR, Tovoli F, Chon HJ, Kang B, Kim C, Imaoka H, Ikeda M, Kudo M, Aoki T, Tortora R, Guarracino M, Stefanini B, Marseglia M, Sparacino A, Celsa C, Bruccoleri M, Alimenti E, Marra F, Campani C, Bhoori S, Mazzaferro V, Sacco R, Facciorusso A, Martini A, Stella L, Cerrito L, Toyoda H, Yasuda S, Rossari F, Rimini M, Suda G, Sho T, Masi G, Vivaldi C, Pressiani T, Kakizaki S, Naganuma A, Avallone A, Nappi A, Vidili G, Soldà C, Bergamo F, Pinato DJ, Pelizzaro F, Foschi FG, Secomandi A, Verderame F, Bronte E, Martinelli E, Marino D, Grasselli S, Olivani A, Brunetto MR, Damone F, Mega A, Marzi L, Tamburini E, Ramundo M, Federico P, Daniele B, Giannini EG, Pasta A, et al. Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study. Liver Cancer. 2025 Aug 5 Journal Impact Factor: 9.1 42. Vespa E, Viale E, Fasulo E, Barchi A, Marabotto E, Pesce M, Piccirelli S, Pasta A, Mandarino FV, Fanizza J, Fratto MC, Cesaro P, Sarnelli G, Passaretti S, Danese S, Savarino EV. Esophageal Function Testing Identifies Barrett's Esophagus Patients With Pathological Acid Exposure at Risk for Neoplasia. Clin Gastroenterol Hepatol. 2025 Oct 25:S1542-3565(25)00925-5. Journal Impact Factor: 12.2 43. Formisano E, Di Cino E, Nicosia E, Pasta A, Paccione G, Sukkar AA, Pisciotta L, Sukkar SG. Prevalence of Dysphagia and Its Health Implications Among Elderly Residents in Long-Term Care Facilities in the Liguria Region (Italy): An Observational Cohort Study. Nutrients. 2025 Oct 17;17(20):3268. Journal Impact Factor: 5.0 44. Mocci G, Tursi A, Scaldaferri F, Napolitano D, Pugliese D, Maconi G, Cataletti G, Pica R, Cassieri C, Savarino EV, De Barba C, Costa F, Ceccarelli L, Marzo M, Elisei W, Monterubbianesi R, Faggiani R, Lombardi G, Patturelli M, Ribaldone DG, Bertani L, Rodinò S, Sebkova L, Bodini G, Pasta A, et al. Upadacitinib's Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study. J Clin Med. 2025 Nov 3;14(21):7801. Journal Impact Factor: 2.9 45. Ferrari D, Siboni S, Sozzi M, Visaggi P, Kristo I, Tolone S, Marabotto E, Bernardi D, Schoppmann SF, Rogers BD, Hobson A, Haworth J, Lee YY, Louie BE, Masuda T, Ivy ML, Milito P, Centorrino E, Theodorou D, Triantafyllou T, Pasta A, et al. The Milan Score Predicts Objective Gastroesophageal Reflux Disease in Patients With Type 2 Esophagogastric Junction. Neurogastroenterol Motil. 2026 Jan;38(1):e14987 Journal Impact Factor: 2.9 46. Formisano E, Pasta A, Squeri C, Robotti PC, Pisciotta L. Nutritional knowledge and dietary practices in semi-professional and professional Italian soccer players. J Sports Med Phys Fitness. 2026 Jan;66(1):65-71. Journal Impact Factor: 1.3 47. Pasta A, Rossi DM, Labanca S, Marenco S, Pieri G, Mezzacappa C, Strazzabosco M, Giannini EG. Health inequalities in patients with cirrhosis: Investigating the impact of material deprivation on patients' outcomes. Dig Liver Dis. 2026 Apr;58(4):517-526. Journal Impact Factor: 3.8 48. Calabrese F, Pasta A, Furnari M, Bodini G, Grillo F, Mastracci L, Sorge A, Coletta M, Penagini R, Vecchi M, Marinoni B, Aldinio G, Pessarelli T, Visaggi P, De Bortoli N, Maniero D, Giannini EG, Savarino EV, Marabotto E. Evaluation of the diagnostic accuracy of two esophageal biopsy sites compared to three in histological follow-up of eosinophilic esophagitis - A multicentric study. Dig Liver Dis. 2026 Apr;58(4):488-492. Journal Impact Factor: 3.8 49. Usai Satta P, Astegiano M, Pasta A, Romano A, Ciprandi G, Brandimarte G. The SymbioCare initiative: management of irritable bowel syndrome, comparison between Italian gastroenterologists and general practitioners. Minerva Gastroenterol. 2026 Feb 19. doi:10.23736/S2724-5985.25.03987-7. Journal Impact Factor: 1.5 50. Giannini EG, Pasta A, Pieri G, Labanca S, Marenco S, Strazzabosco M, et al. Comparative Efficacy of Initial Treatment Strategies in Patients With TACE-Unsuitable Hepatocellular Carcinoma. Liver Cancer. 2026 Feb 19. Journal Impact Factor: 9.1 51. Tursi A*, Pasta A*, Elisei W, Barberio B, Mocci G, Savarino EV, et al. Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis. Clin Pharmacol Ther. 2026 Mar 5. (*co-first authorship) Journal Impact Factor: 5.5 52. Tursi A, Mocci G, Costa F, Ceccarelli L, Savarino E, De Barba C, Mucherino C, D'Antonio E, Montesano L, Marzo M, Scaldaferri F, Napolitano D, Pugliese D, Gravina AG, Pellegrino R, Spagnuolo R, Luzza F, Cuomo A, Donnarumma L, Maconi G, Cataletti G, Bertani L, Bodini G, Pasta A, et al. Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study. Intest Res. 2026 Apr;24(2):341-351. Journal Impact Factor: 3.9 53. Tursi A, Pasta A, Elisei W, Barberio B, Mocci G, Savarino EV, et al.; Italian Network for Inflammatory Bowel Diseases (IN-IBD). Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study. Adv Ther. 2026 May 9 Journal Impact Factor: 4.1 54. Kayali S, Dibitetto S, Busatto A, Gaiani F, Pasta A, Calabrese F, Fantasia S, Caprioli S, Luzzi AP, De Angelis CG, Savarino EV, Laghi L, Giannini EG, Marabotto E. Optimizing branch-duct intraductal papillary mucinous neoplasms surveillance: Data-driven dimensional grouping for risk stratification and cost-effectiveness. World J Gastroenterol. 2026 May 28;32(20):114867. doi:10.3748/wjg.v32.i20.114867. Journal Impact Factor: 5.4 GUIDELINES 1. Mari A, Calabrese F, Pasta A, et al. Esophageal and Oropharyngeal Dysphagia: Clinical Recommendations From the United European Gastroenterology and European Society for Neurogastroenterology and Motility. United European Gastroenterol J. 2025 Jul;13(6):855-901. doi: 10.1002/ueg2.70062. Epub 2025 Jun 21. Erratum in: United European Gastroenterol J. 2025 Oct;13(8):1607. doi: 10.1002/ueg2.70088. Journal Impact Factor: 6.7 REVIEWS 1. Pasta A, Cremonini AL, Pisciotta L, Buscaglia A, Porto I, Barra F, Ferrero S, Brunelli C, Rosa GM. PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin Pharmacother. 2020;21(3):353-363. Journal Impact Factor: 2.7 2. Pasta A, Kayali S, Borro P. The study of hepatic fibrosis: state of art and future perspectives. Gazz Med Ital - Arch Sci Med. 2022;180(12) Journal Impact Factor: not reported; CiteScore: 0.2 3. Kayali S*, Pasta A*, Plaz Torres MC, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.Liver Int. 2023;43(1):8-17. (*co-first authorship) Journal Impact Factor: 5.2 4. Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Intagliata NM, Caldwell SH, Giannini EG. Safety and efficacy of venous thromboembolism prophylaxis in patients with cirrhosis: A systematic review and meta-analysis. Liver Int. 2023 Jul;43(7):1399-1406. Journal Impact Factor: 5.2 5. Marabotto E, Mari A, Calabrese F, Pasta A, Djahandideh Sheijani S, Giannini EG, Savarino V, Savarino E. Biliary reflux after bariatric surgery and after gastroesophageal surgery for gastroesophageal reflux disease. Dig Med Res. 2024;7:2 Journal Impact Factor: not reported; CiteScore: 0.6 6. Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Strazzabosco M, Giannini EG. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer. 2023 Oct 14;13(3):227-237. Journal Impact Factor: 9.1 7. Pasta A, Formisano E, Calabrese F, Plaz Torres MC, Bodini G, Marabotto E, Pisciotta L, Giannini EG, Furnari M. Food Intolerances, Food Allergies and IBS: Lights and Shadows. Nutrients. 2024 Jan 16;16(2):265. Journal Impact Factor: 5.0 8. Visaggi P, Ghisa M, Vespa E, Barchi A, Mari A, Pasta A, Marabotto E, de Bortoli N, Savarino EV. Optimal Assessment, Treatment, and Monitoring of Adults with Eosinophilic Esophagitis: Strategies to Improve Outcomes. Immunotargets Ther. 2024 Jul 24;13:367-383. Journal Impact Factor: 4.4 9. Gravina AG, Pellegrino R, Palladino G, Imperio G, Calabrese F, Pasta A, Giannini EG, Federico A, Bodini G. Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand. Biomolecules. 2024 Sep 17;14(9):1164 Journal Impact Factor: 4.8 10. Marabotto E, Pasta A, Calabrese F, Ribolsi M, Mari A, Savarino V, Savarino EV. The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions. Visc Med. 2024 Oct;40(5):242-249 Journal Impact Factor: 1.6 11. Visaggi P, Bertin L, Pasta A, Calabrese F, Ghisa M, Marabotto E, Ribolsi M, Savarino V, de Bortoli N, Savarino EV. Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024. Expert Opin Pharmacother. 2024 Oct;25(15):2077-2088. Journal Impact Factor: 2.7 12. Marabotto E, Calabrese F, Pasta A, Visaggi P, de Bortoli N, Mari A, Tolone S, Ghisa M, Bertin L, Savarino V, Savarino EV. Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults. Expert Opin Pharmacother. 2024 Dec;25(17):2319-2325. Journal Impact Factor: 2.7 13. Pasta A, Calabrese F, Marabotto E, Furnari M, Demarzo MG, Pellegrino R, Gravina AG, Federico A, Giannini EG, Bodini G. Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn's Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies. Diseases. 2024 Nov 19;12(11):295. Journal Impact Factor: 3.0 14. Giannini EG, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, Plaz Torres MC, Strazzabosco M. Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis. Liver Int. 2025 Jan;45(1):e16222. Journal Impact Factor: 5.2 15. Savarino V, Visaggi P, Marabotto E, Bertin L, Pasta A, Calabrese F, Zentilin P, Ghisa M, Ribolsi M, Mari A, Tolone S, de Bortoli N, Savarino EV. Topical Protection of Esophageal Mucosa as a New Treatment of GERD. J Clin Gastroenterol. 2025 Mar 1;59(3):197-205. Journal Impact Factor: 2.7 16. Pasta A, Formisano E, Calabrese F, Marabotto E, Furnari M, Bodini G, Torres MCP, Pisciotta L, Giannini EG, Zentilin P. From Dysbiosis to Hepatic Inflammation: A Narrative Review on the Diet-Microbiota-Liver Axis in Steatotic Liver Disease. Microorganisms. 2025; 13(2):241 Journal Impact Factor: 4.2 17. Pasta A, Facciorusso A, Plaz Torres MC, Giannini EG, Sacco R. Effects of glucagon-like PEPTIDE-1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META-analysis. Eur J Clin Invest. 2025;55(6):e70000 Journal Impact Factor: 3.6 18. Pasta A, Calabrese F, Furnari M, Savarino EV, Visaggi P, Bodini G, Formisano E, Zentilin P, Giannini EG, Marabotto E. Endoscopic Management of Eosinophilic Esophagitis: A Narrative Review on Diagnosis and Treatment. Journal of Clinical Medicine. 2025; 14(11):3756. Journal Impact Factor: 2.9 19. Bertin L, Pasta A, Ghisa M, Calabrese F, Visaggi P, de Bortoli N, Savarino V, Marabotto E, Savarino EV. Research gaps in eosinophilic esophagitis: unanswered questions and future directions. Dig Liver Dis. 2026 Jan;58(1):23-37. Journal Impact Factor: 3.8 20. Calabrese F, Pasta A, Bertin L, Formisano E, Siboni S, Furnari M, Arrigo S, Visaggi P, Savarino EV, Giannini EG, Marabotto E. Updated treatment options for gastroesophageal reflux disease in children: practical guide for clinicians. Expert Opin Pharmacother. 2025 Nov;26(16):1631-1648. Journal Impact Factor: 2.7 21. Calabrese F, Pasta A, Formisano E, Marabotto E, Furnari M, Pisciotta L, Zentilin P, Giannini EG, Bodini G. Diet in Inflammatory Bowel Diseases: Efficacy, Tolerability, and Microbiome Effects Toward Personalized Management. Dig Dis Sci. 2025 Nov 28. Journal Impact Factor: 2.5 22. Pasta A, Bertin L, Mari A, Calabrese F, Farah A, Navazzotti G, Ghisa M, Savarino V, Savarino EV, Giannini EG, Marabotto E. The Therapeutic Pipeline for Eosinophilic Esophagitis: Current Landscape and Future Directions. Pharmaceuticals (Basel). 2025 Dec 12;18(12):1882. Journal Impact Factor: 4.8 23. Bertin L*, Pasta A*, Wechsler JB, Ghisa M, Calabrese F, Navazzotti G, Grillo F, Mastracci L, Visaggi P, de Bortoli N, Fassan M, Marabotto E, Savarino EV. Beyond Eosinophils: Redefining the Spectrum of Esophageal Inflammatory Diseases Through an Immune-Centric Paradigm. Clin Gastroenterol Hepatol. 2026 May;24(5):1220-1231 (*co-first authorship) Journal Impact Factor: 12.2 24. Pasta A, Formisano E, Calabrese F, Navazzotti G, Giannini EG, Savarino V, Savarino EV, Marabotto E. Dietary and nutraceutical interventions for functional dyspepsia: A narrative review. Dig Liver Dis. 2026 Apr 5. Journal Impact Factor: 3.8 25. Bertin L, Caldart F, Barchi A, Seregni N, Pasta A, Calabrese F, Marabotto E, Mari A, Farah A, Sirinic E, Sorge A, Ghisa M, Chahuán J, Savarino V, Savarino EV. The immune architecture of eosinophilic esophagitis: Mechanisms, therapeutic targets, and precision management. Immunotargets Ther. 2026 May 27;15:510865. Journal Impact Factor: 4.4 26. Papadia FS, Karcz KW, Pasta A, Giannini E. Chronic Liver Disease, Liver Damage and Liver Failure After Hypoabsorptive Bariatric Surgery: A Dose-Dependent Relationship and Multisystemic Consequences. Eur J Clin Invest. 2026;56. Journal Impact Factor: 3.6 EDITORIALI 1. Calabrese F, Pasta A, Bodini G, Furnari M, Zentilin P, Giannini EG, Maniero D, Casa DD, Cataudella G, Frazzoni M, Penagini R, Elena A, De Bortoli N, Visaggi P, Savarino V, Savarino E, Marabotto E. Editorial: Diagnosis of GERD in patients with extra-oesophageal symptoms-still a long way to go… Authors' reply'. Aliment Pharmacol Ther. 2024 May;59(9):1150-1151 Journal Impact Factor: 6.7 2. Navazzotti G, Marabotto E, Pasta A, Calabrese F, Zentilin P, Furnari M, Bodini G, Giannini EG, Savarino EV, Savarino V. The promise and pitfalls of emerging potassium-competitive acid blockers for the treatment of gastroesophageal reflux disease. Expert Opin Pharmacother. 2026;27(1):5-8. Journal Impact Factor: 2.7 CASE REPORTS 1. Djahandideh Sheijani S, Calabrese F, Pasta A, Marabotto E, Bodini G, Furnari M, Grillo F, Mastracci L, Savarino EV, Savarino V, Giannini EG. Clopidogrel-induced Eosinophilic Colitis. ACG Case Rep J. 2023 Aug 3;10(8):e01118 Journal Impact Factor: 0.5 2. Geremicca G, Labanca S, Pasta A, Pieri G, Marenco S, Cariati S, Grossi A, Giannini EG. Resolution of Hepatitis Delta Virus-Related Cryoglobulinemic Vasculitis With the Use of Bulevirtide. ACG Case Rep J. 2026 Mar 23;13(3):e02046 Journal Impact Factor: 0.5 3. Ziola S, Cittadini G, Pasta A, Labanca S, Pieri G, Marenco S, Giannini EG. Recurrent Hepatic Encephalopathy After Abdominal Surgery in a Non-Cirrhotic Patient: A Case Report. Reports. 2026 Apr 6;9(2):112. Journal Impact Factor: 0.6 LETTERE 1. Pasta A, Calabrese F, Giannini EG. Assessing the Short-Term Prognosis of Patients with Cirrhosis Using the DIC Scores. Thromb Haemost. 2023 Mar 24. Journal Impact Factor: 4.3 2. Marabotto E, Pasta A, Calabrese F et al. Is global score better than a single histological parameter for assessing microscopic esophagitis?. Neurogastroenterol Motil. 2024 Jan;36(1):e14685. Journal Impact Factor: 3.3 3. Pasta A, Calabrese F, Plaz Torres MC, Bodini G, Furnari M, Savarino EV, Savarino V, Giannini EG, Marabotto E. Albumin-bilirubin score in non-malignant liver diseases should be properly validated. World J Gastroenterol. 2023 Dec 14;29(46):6089-6091. Journal Impact Factor: 5.4 4. Barbera L, Pasta A, Calabrese F, Zentilin P, Fragale M, Barbieri M, Peretti G, Savarino EV, Giannini EG, Marabotto E. Evaluation of the pathophysiological association between the GERD and OSAS: Esophageal pH-monitoring results beyond Lyon criteria. J Gastroenterol Hepatol. 2024 Apr;39(4):772. Journal Impact Factor: 3.4 5. Labanca S, Pasta A, Cariati S, Calabrese F, Pieri G, Plaz Torres MC, Marenco S, Giannini EG. Is CAD-LT score as a predictor of coronary artery disease following liver transplantation? Liver Transpl. 2024 May 1;30(5) Journal Impact Factor: 4.2 3. Pasta A, Calabrese F, Bodini G. Response to Letter to Editor on "Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission". J Gastrointestin Liver Dis. 2024 Jun 29;33(2):281. Journal Impact Factor: 2.0 4. Giannini EG, Pasta A, Labanca S, Pieri G, Marenco S, Plaz Torres MC. Surveillance for hepatocellular carcinoma in patients with primary biliary cholangitis: For all or just for some? JHEP Rep. 2025 Feb 19;7(6):101362. Journal Impact Factor: 7.5 5. Pasta A, Pieri G, Giannini EG; Italian Liver Cancer (ITA.LI.CA) Group. Changing epidemiology of hepatocellular carcinoma in the Mediterranean area: A challenge for surveillance? JHEP Rep. 2025 Mar 12;7(7):101396. Journal Impact Factor: 7.5 6. Pasta A, Giannini EG. It takes two to tango: Preserving liver function competes with response to systemic therapy in patients with HCC and decompensated cirrhosis. Dig Liver Dis. 2025 Dec;57(12):2510-2511 Journal Impact Factor: 3.8 6. Calabrese F, Pasta A, Savarino EV, Savarino V, Giannini EG, Marabotto E. Expanding Insights on Ambulatory Reflux Monitoring: Future Directions and Clinical Integration. Am J Gastroenterol. 2025 Apr 1;120(4):928-929. World J Gastroenterol Journal Impact Factor: 5.4 7. Pasta A, Calabrese F, Savarino EV, Giannini EG, Marabotto E. Role of prokinetics in ineffective esophageal motility: A call for broader consideration and future innovations. Neurogastroenterol Motil. 2025 Feb;37(2):e14961. Journal Impact Factor: 3.3 8. Pasta A, Pieri G, Giannini EG; Italian Liver Cancer (ITA.LI.CA) Group. Autoimmune Hepatitis-Associated Hepatocellular Carcinoma: Clarifying the Evidence-A Reply. Dig Dis Sci. 2025 Oct;70(10):3587-3588. Journal Impact Factor: 9.1 9. Calabrese F, Pasta A, Savarino EV, Giannini EG, Marabotto E. Mean Nocturnal Baseline Impedance in Gastroesophageal Reflux Disease: Considerations on the Study by Lee et al. J Neurogastroenterol Motil. 2026 Jan 30;32(1):136-137. Journal Impact Factor: 3.3 10. Giannini EG, Labanca S, Marenco S, Pieri G, Calabrese F, Pasta A. Sustained Virologic Response and Prognosis in Hepatitis C Virus-Related Hepatocellular Carcinoma: Lessons from Complementary Cohorts. Oncology. Published online February 5, 2026. Journal Impact Factor: 1.8 11. Formisano E, Pasta A, Pisciotta L. Reply to: "Obesity and statin intolerance: Implications for LDL-C target achievement in PCSK9 inhibitor therapy". J Clin Lipidol. 2026 Feb;20(2):458-459. Journal Impact Factor: 4.6 ARTICOLI COLLABORATIVI 1. Casula M, Olmastroni E, Pirillo A, Catapano AL; MEMBERS OF THE LIPIGEN STEERING COMMETTEE; PRINCIPAL INVESTIGATORS: Coordinator center; Participant Centers; Participant Laboratories; COLLABORATORS; STUDY CENTRAL LABORATORY AND ANALYSIS GROUP. Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis. 2018;277:413-418. Journal Impact Factor: 5.7 2. Casula M, Gazzotti M, Bonaiti F, OImastroni E, Arca M, Averna M, Zambon A, Catapano AL & on behalf of the PROSISA Study Group. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. J Intern Med. 2021;290(1):116-128. Journal Impact Factor: 9.2 3. Bertolini S, Calandra S, Arca M, Averna M, Catapano AL, Tarugi P; Italian Study Group of Homozygous Familial Hypercholesterolemia. Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features Atherosclerosis. 2020;312:72-78. Journal Impact Factor: 5.7 4. Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-Shiba M, Blom DJ, Raal FJ, Cuchel M; Homozygous Familial Hypercholesterolaemia International Clinical Collaborators. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet. 2022;399(10326):719-728 Journal Impact Factor: 88.5 5. Pelizzaro F, Trevisani F, Simeon V, Vitale A, Cillo U, Piscaglia F, Missale G, Sangiovanni A, Foschi FG, Cabibbo G, Caturelli E, Di Marco M, Azzaroli F, Brunetto MR, Raimondo G, Vidili G, Guarino M, Gasbarrini A, Campani C, Svegliati-Baroni G, Giannini EG, Mega A, Masotto A, Rapaccini GL, Magalotti D, Sacco R, Nardone G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection. Liver Int. 2023 Dec;43(12):2762-2775. doi: 10.1111/liv.15719. Epub 2023 Sep 27. PMID: 37753540. Journal Impact Factor: 5.2 6. Lani L, Bucci L, Santi V, Stefanini B, Stefanini B, Sangiovanni A, Grasselli S, Ghittoni G, Saitta C, Morisco F, Cabibbo G, Marra F, Vidili G, Brunetto MR, Foschi FG, Di Marco M, Svegliati-Baroni G, Pelizzaro F, Azzaroli F, Ponziani FR, Martini A, Sacerdoti D, Mega A, Boninsegna S, Giannini EG, Magalotti D, Sacco R, Nardone G, Caraceni P, Vitale A, Trevisani F; and the Italian Liver Cancer group. Outcome of hepatic resection for HCC in ideal and non-ideal candidates. Hepatol Commun. 2025 Jul 29;9(8):e0772. 7. Chan WW, Schroeder M, Richardson A, Shah N, Muftah M, Muftah S, Siboni S, Sozzi M, Wong MW, Chen CL, Gyawali CP; Milan Score Working Group. Validation of Esophageal Global Symptom Severity as a Patient-Reported Outcome for Evaluation of Reflux Symptoms. Am J Gastroenterol. 2025 Apr 23;120(8):1760-1769. Journal Impact Factor: 7.6 8. Giuliante F, Famularo S, Grasselli S, Sangiovanni A, Vitale A, Cabibbo G, Lauterio A, Cipriani F, Saccomandi A, Arru M, Pinto E, Brunetto MR, Franzè MS, Graziosi C, Campani C, Marra F, Di Marco M, Marseglia M, Santi V, Capasso M, Masotto A, Fontana A, Iaria M, Rocco A, Serenari M, Mega A, Gasbarrini A, Plaz Torres MC, Garancini M, Conci S, Dajti E, Perri P, Sacco R, Giglio M, Ferari C, De Angelis M, Troci A, Magalotti D, Nicolini D, Zimmitti G, Germani P, Schiadà L, Conticchio M, Zanello M, Romano M, Milana F, Lai Q, Patauner S, Frena A, Rossi M, Torzilli G, Zanus G, Jovine E, Memeo R, Svegliati-Baroni G, Tarchi P, Hilal MA, Vivarelli M, Crespi M, Boccia L, Griseri G, Troisi RI, Grazi GL, Azzaroli F, Ruzzenente A, Romano F, Giannini EG, Cescon M, Nardone G, Valle RD, Ferrero A, Morisco F, Piscaglia F, Ghittoni G, Saitta C, Pelizzaro F, Vidili G, Foschi FG, Aldrighetti L, De Carlis L, Cillo U, Biasini E, Bernasconi D, Ardito F, Trevisani F; HE.RC.O.LE.S. and the ITA.LI.CA. groups. Minimally invasive hepatectomy vs. thermoablation for single small (≤3 cm) hepatocellular carcinoma: A weighted real-life national comparison. JHEP Rep. 2025 Apr 25;7(8):101420. Journal Impact Factor: 7.5 9. Pinto, E, Pelizzaro, F, Simeon, V, Bucci, L, Gambato, M, Vitale, A, Sangiovanni, A, Cabibbo, G, Ghittoni, G, Svegliati-Baroni, G, Boninsegna, S, Trevisani, F, Foschi, F G, Stefanini, B, Saitta, C, Azzaroli, F, Marra, F, Vidili, G, Mega, A, Zaccherini, G, … ITA.LI.CA study group (2026). Tumour Burden Score as a Predictor of Extrahepatic Progression After Transarterial Chemoembolization for Hepatocellular Carcinoma: An Observational Multicenter Study. Alimentary pharmacology & therapeutics, 10.1111/apt.70534. Journal Impact Factor: 6.7
Mostra dettagli

Premi e riconoscimenti

  • Premio “RAFFAELE SOSTEGNI” al Congresso Nazionale Ig-IBD per la migliore comunicazione orale per il lavoro dal titolo “L'uso della dieta di esclusione per la malattia di Crohn (CDED) negli adulti con malattia di Crohn: uno studio randomizzato controllato"

Profili social

Prenota una visita

Prestazioni e prezzi

  • Visita gastroenterologica

  • Visita epatologica

  • Visita epatologica di controllo

  • Visita gastroenterologica di controllo

Indirizzi (2)

Andrea Pasta
Centro Medico Fieschi

Via Fieschi, 8/13, Genova 16121

Vedi mappa si apre in una nuova scheda

Disponibilità

Modalità di pagamento (visite private)

  • Carta di credito
  • Carta di debito
  • Carta prepagata
  • Contanti

Telefono

010 984...

Telefono

Centro Medico Fieschi

Potrebbe essere necessario fornire alcuni dati affinché possiamo crearti un account come paziente su MioDottore. Fornendo i tuoi dati accetti i nostri termini e condizioni di servizio e la nostra politica della privacy.

Risparmia tempo! Prenota online:

Prenota senza telefonare e senza costi aggiuntivi, selezionando una data disponibile. Dopo la prenotazione riceverai email di conferma e promemoria tramite SMS.

Puoi anche inviare un messaggio

Tempo medio di risposta:

Dettagli dell'indirizzo

Presso questo indirizzo visito
  • Adulti
Contatti
Sito web si apre in una nuova scheda
Prestazioni disponibili

Prestazioni disponibili

Centro Medico Fieschi

Hai dubbi o domande?

Tempo medio di risposta:

Invia messaggio
Prenota una visita
Andrea Pasta
Studio Medico La Corte

Piazza Borgo Pila, 40, Torre A - 2 piano int. 14, Genova 16129

Vedi mappa si apre in una nuova scheda

Disponibilità

Telefono

010 984...

Telefono

Studio Medico La Corte

Potrebbe essere necessario fornire alcuni dati affinché possiamo crearti un account come paziente su MioDottore. Fornendo i tuoi dati accetti i nostri termini e condizioni di servizio e la nostra politica della privacy.

Risparmia tempo! Prenota online:

Prenota senza telefonare e senza costi aggiuntivi, selezionando una data disponibile. Dopo la prenotazione riceverai email di conferma e promemoria tramite SMS.

Puoi anche inviare un messaggio

Tempo medio di risposta:

Dettagli dell'indirizzo

Prestazioni disponibili

Prestazioni disponibili

Studio Medico La Corte

Hai dubbi o domande?

Tempo medio di risposta:

Invia messaggio
Prenota una visita

Convenzioni assicurative non attive

Questo dottore accetta solo pazienti privati. Verrà richiesto un pagamento da parte tua per la prestazione o puoi ricercare un altro dottore che abbia una convenzione con la tua assicurazione

Recensioni

Aggiungi una recensione

25 recensioni

Più menzionato dai pazienti

  • Spiegazioni dettagliate
  • Attenzione durante la visita
  • Puntualità
Tutte le recensioni contano e non possono essere rimosse o modificate dai dottori a proprio piacimento. Scopri come funziona il processo di moderazione delle recensioni. Per saperne di più sulle opinioni
  • G

    Giulia C.

    Medico molto competente, preparato, ti ascolta sono molto soddisfatta

     • Studio Medico La Corte • visita gastroenterologica  • 
  • L

    L.S.

    Medico molto competente. Si è dimostrato premuroso nell'assicurarsi che avessi compreso perfettamente la terapia prescrittami spiegandomene il razionale e i possibili effetti avversi.

     • Centro Medico Fieschi • visita epatologica  • 

  • C

    Consiglio veramente il Dottor Pasta, ha ascoltato con attenzione tutti i miei problemi e ha capito subito come procedere. Molto empatico e disponibile, ho avuto bisogno di un consiglio urgente e mi ha risposto in fretta.

     • Centro Medico Fieschi • visita gastroenterologica  • 
  • A

    Amadei Graziella

    Dottore molto gentile disponibile e la cosa fondamentale molto preparato !!! Tutto perfetto

     • Centro Medico Fieschi • visita gastroenterologica  • 
  • E

    E. F.

    Un medico davvero competente, gentile nei modi, chiaro nelle spiegazioni

     • Centro Medico Fieschi • visita gastroenterologica  • 
  • F

    Ferrari

    Ottimo professionista giovane molto preparato e scrupoloso consiglio vivamente per la capacità di ascolto e di andare al punto della situazione avendo un approccio oggettivo di esclusione e individuando la causa dei sintomi.. altri professionisti erano stati molto superficiali.. come in tutti i lavori la persona fa la differenza!!

     • Centro Medico Fieschi • visita gastroenterologica  • 
  • A

    A.M

    Molto professionale e attento alle mie problematiche.
    Molto soddisfatta.

     • Centro Medico Fieschi • visita gastroenterologica  • 
  • M

    Monica Eyzantier

    Empatico è molto professionale mette a proprio agio e ascolta

     • Centro Medico Fieschi • visita gastroenterologica  • 
  • D

    Daniela

    Una bella persona e attenta alle problematiche descritte da me

     • Centro Medico Fieschi • visita gastroenterologica  • 
  • G

    G.i.

    Dottore preciso, attento al paziente. Molto professionale.

     • Centro Medico Fieschi • visita gastroenterologica  • 
Si è verificato un errore, riprova
Città vicino Genova
Principali patologie trattate

Informazioni sul prezzo

Centro Medico Fieschi

I prezzi di alcune prestazioni possono variare a seconda del singolo caso. Dopo aver effettuato una prenotazione, puoi chiedermi il prezzo di una specifica prestazione inviandomi un messaggio privato. Prenota ora la data più adatta alle tue esigenze.

Hai dubbi o domande?

Tempo medio di risposta:

La prenotazione e la cancellazione della visita sono servizi gratuiti

Hai dubbi o domande?

Tempo medio di risposta:

Informazioni sul prezzo

Studio Medico La Corte

I prezzi di alcune prestazioni possono variare a seconda del singolo caso. Dopo aver effettuato una prenotazione, puoi chiedermi il prezzo di una specifica prestazione inviandomi un messaggio privato. Prenota ora la data più adatta alle tue esigenze.

Hai dubbi o domande?

Tempo medio di risposta:

La prenotazione e la cancellazione della visita sono servizi gratuiti

Hai dubbi o domande?

Tempo medio di risposta:

E' necessario il pagamento della tua visita

Il dottore con cui hai prenotato richiede di effettuare il pagamento. Per riprogrammare il tuo appuntamento, procedi con il pagamento oppure contatta direttamente il dottore.
Le mie visite Paga